Stimuli of prostacyclin (PGI2) biosynthesis such as thrombin, bradykinin, histamine, and A23187 increase guanosine 3',-cyclic monophosphate (cyclic GMP) levels in primary monolayer cultures of human umbilical vein endothelium by about twofold.
Introduction
The interaction of extracellular messengers with specific cell surface receptors results in the formation of intracellular messengers that ultimately mediate cellular activation. Most tissues appear to possess two major classes of receptors for controlling cellular function and proliferation; one class triggers the production of cyclic AMP while the other induces inositol phospholipid turnover. It is now accepted that phosphatidylinositol breakdown constitutes an important part of the receptor mechanism involved in the elevation of cytosolic Ca2+ (reviewed in references 1-4). Ca2' mobilization by physiological stimuli appears to be closely associated with the receptor-activated hydrolysis of phosphatidylinositol 4,5-bisphosphate to 1,2-diacylglycerol and inositol 1,4,5-trisphosphate. Inositol 1,4,5-trisphosphate has been directly implicated in the release of Ca2" from the endoplasmic reticulum into the cytosol while 1,2-diacylglycerol has also been shown to act as a signal molecule by enhancing the Ca2`sensitivity of protein kinase C (1) (2) (3) (4) . In several cell types the stimulation ofphosphatidylinositol hydrolysis and Ca2' mobilization leads to the release of arachidonic acid and its metabolites, and has been found to increase guanosine 3',5'-cyclic monophosphate (cyclic GMP)' accumulation (3, 4) . Thus, Ca2+ mobilization, arachidonic acid release, and cyclic GMP formation appear to be integrated in a single receptor cascade.
Although a wide variety of agents stimulate prostacyclin (PGI2) biosynthesis in vascular endothelium (reviewed in reference 5), little is known regarding the specific mechanisms involved in the induction and regulation of PGI2 production. Results of previous studies (6) demonstrate that cyclic AMP does not mediate the effects of stimuli of PGI2 biosynthesis, nor does it appear to be involved in the short-term regulation of PGI2 production in primary cultures of human umbilical vein endothelium. Conversely, Ca(+ does appear to have a predominant role as an intracellular mediator in the secretory processes of endothelial cells, as Ca2`ionophores such as A23 187 can stimulate PGI2 production (5) (6) (7) (8) . It has not yet been demonstrated that extracellular signals such as thrombin, bradykinin, and histamine stimulate Ca2' mobilization in endothelial cells via phosphatidylinositol hydrolysis. In light of the close association between the stimulation of phosphatidylinositol hydrolysis and increased cyclic GMP accumulation that has been observed in many cell types (3, 4) , the present study was carried out to determine whether a similar relationship exists in cultured endothelium with respect to the induction of PGI2 biosynthesis.
The studies reported in this paper demonstrate that the induction of PGI2 biosynthesis in primary cultures of human umbilical vein endothelium is closely associated with a rapid increase in the intracellular concentration of cyclic GMP, and, that this increase in cyclic GMP results from the activation of guanylate cyclase by factors generated before the release and metabolism of arachidonic acid.
Methods
Materials. Unless noted otherwise, supplies and reagents were purchased from Sigma Chemical Co., St. Louis, MO. Other materials included: Type I collagenase from Cooper Biochemical Inc., Malvern, PA; powdered Medium 199 (with Earle's salts, with L-glutamine, and without NaHCO3), Eagle's basal medium vitamin solution (X 100), Eagle's basal medium amino acid solution (X 100), L-glutamine, and neomycin sulfate from Gibco, Grand Island, NY; fetal calf serum (FCS) Endothelial cell cultures. Primary cultures of human endothelial cells from umbilical cords were prepared by a modification of the method originally described by Jaffe et al. (10) . Umbilical cords <24-h-old were cleaned and the veins rinsed free ofblood with phosphate-buffered saline (PBS), pH 7.4 (0.14 M NaCl, 0.003 M KCI, 0.0012 M KH2PO4, 0.008 M Na2HPO4, and 0.01 g/liter phenol red). Cords were clamped and the vein was filled with PBS containing 0.1% Type I collagenase. Enzymatic digestion wag continued for 6 min at room temperature. The vein was drained and then rinsed with a total of -50 ml of modified Medium-199 (MM-199) (8) containing 10% heat-inactivated FCS. The cells were sedimented at 300 g for 10 min and then resuspended with -5-10 ml of MM-199 with 20% FCS. The cell count ofthe suspension was adjusted to 4.5 X I0 cells/ml; 1 ml of this suspension was added to each well of a 12-well tissue culture plate. Cells were incubated at 37°C under 5% CO2. 4 h after seeding, the medium was removed and the monolayers were rinsed with 1 ml of MM-199; 1 ml of with buffer before the acetylation step. Eight concentrations of cyclic GMP are included in the standard curve, which ranges from 2.5 to 500 fmol/40 Ml. After incubation at 4VC for 16-24 h, 1 ml of ice-cold 95% ethanol was added to each tube to precipitate bound radioactivity. The tubes were then centrifuged at 2,000 g for 15 min at 4VC, the supernates aspirated, and the dried precipitates counted on a DP 5000 gamma counter (Beckman Instruments Inc.). Under these conditions, 50% dis-
from cyclic GMP is obtained with 12-15 fmol ofcyclic GMP/40 Ml, and -30% of average net total counts are bound in the absence of cyclic GMP. All samples were assayed at a minimum oftwo dilutions and the concentration of cyclic GMP was corrected for recovery. Statistical analysis. Statistical significance was determined by the Students t test; a P value of <0.005 was chosen to denote statistical significance between groups. Unless indicated otherwise, the data are reported as means±SEM of triplicate determinations from the same experiment. In all cases, similar findings were obtained in a minimum of two other experiments.
Results
A wide variety of agents that stimulate PGI2 biosynthesis in primary monolayer cultures of human umbilical vein endothelium have been found to stimulate cyclic GMP accumulation in these cells. As shown in Table I , thrombin, the calcium ionophore A23187, bradykinin, and histamine increased the intracellular concentration of cyclic GMP by an average of about twofold during a 5-min incubation period. By contrast, arachidonic acid had no effect on cyclic GMP accumulation. The concentration ofeach agent tested was selected to stimulate maximal or near-maximal release of PGI2 (see legend of Table I ). To determine whether the observed increases in cyclic GMP resulted from increased synthesis (activation ofguanylate cyclase) or decreased degradation (inhibition of cyclic GMP phosphodiesterase), studies were carried out in the presence of l-methyl-3-isobutylxanthine (MIX), a cyclic nucleotide phosphodiesterase inhibitor. Incubation of endothelial monolayers for a total of 10 min with 1 mM MIX increased the basal level of cyclic GMP by an average of7.4± 1.0-fold (Table I) . Nearly maximal increases (-80%) in cyclic GMP were obtained with 1 mM MIX; maximal increases were observed with 4 mM MIX and half-maximal with 0.5 mM MIX. As shown in Table I , much larger increases in the intracellular concentration of cyclic GMP were obtained in response to stimuli of PGI2 biosynthesis when endothelial monolayers were preincubated with 1 mM MIX. With the exception of arachidonic acid, which had no effect, each of the other agents increased cyclic GMP levels by an average of about tenfold in the presence of MIX (Table I) . Thus, the effects of these treatments are additive. This finding suggests that stimuli of PGI2 biosynthesis that increase the intracellular concentration of cyclic GMP, act by a mechanism involving activation of guanylate cyclase and not inhibition of cyclic GMP phosphodiesterase.
The lack of an effect of arachidonic acid on cyclic GMP accumulation suggests that neither arachidonic acid itself nor its metabolites activate guanylate cyclase in primary human umbilical vein endothelium. Additional evidence in support of this hypothesis is provided by studies of the effects of inhibitors ofarachidonic acid release and of its subsequent metabolism on both PGI2 production and cyclic GMP accumulation. These agents included: quinacrine, an inhibitor of phospholipase A2; aspirin and ibuprofen, cyclooxygenase inhibitors; and 5,8,11,14-eicosatetraynoic acid (ETYA), a lipoxygenase inhibitor. As shown in Table II , pretreatment of endothelial monolayers with 100 ,M quinacrine decreased PGI2 production in response to thrombin and A23187 by -69 and 52%, respectively, but had no effect on the stimulation of cyclic GMP accumulation by either of these agents in the absence or presence of MIX. Note that quinacrine had no effect on PGI2 production in response to arachidonic acid. In monolayers that had been pretreated with 100 ,M aspirin or 500 ,uM ibuprofen, PGI2 production in response to all stimuli tested was abolished; however, the stimulation of cyclic GMP accumulation was unaffected. Similar findings were obtained with ETYA at concentrations ranging from 1 to 20 1AM. Taken together, these results suggest that the increase in cyclic GMP observed in response to stimuli of PGI2 production results from the activation of guanylate cyclase by factors generated before the release and metabolism of arachidonic acid.
To examine the role of extracellular C(7i in the induction ofPGI2 biosynthesis and cyclic GMP accumulation, experiments were carried out using Ca2+-free buffer (Hanks'-Hepes buffer with 1.3 mM CaC2 omitted). Incubations were as described in Methods, with the exception that monolayers were rinsed three times with 1 ml of Ca(-free Hanks'-Hepes buffer before the addition of the test stimulus. Endothelial monolayers were also grown on fibronectin-coated plates, as preliminary studies showed that omission ofCa2E from the buffer resulted in partial detachment of the monolayers from the surface of the tissueculture plate. As shown in Table III , omission of Ca2' had no significant effect on PGI2 production in response to stimulation by thrombin. By contrast, the effect of A23187 was decreased by -40% as compared with values obtained in the presence of Ca2'. However, neither thrombin nor A23187 had a significant effect on cyclic GMP accumulation in the absence ofboth Ca2( and MIX. In monolayers that had been preincubated with 1 mM MIX, thrombin and A23 187 increased cyclic GMP levels by an average of only 2.0-and 3.4-fold, respectively, in Ca2+-free buffer, whereas increases of 7.6-and 6.6-fold, respectively, were observed in the presence of extracellular Ca2+ (Table III) . Thus, the stimulatory effect of thrombin on cyclic GMP accumulation appears to be more dependent on the availability of extracellular Ca2' than the effect of A23 187. Significant differences therefore exist with respect to the requirements of the endothelium for extracellular Ca2+ for the stimulation of PG12 biosynthesis as compared with cyclic GMP accumulation in response to thrombin or A23187 (Table III) .
The relationship between cyclic GMP accumulation in re- sponse to thrombin and A23 187 and incubation time is shown in Fig. 1 . In monolayers preincubated with buffer alone (Fig. 1  A) , thrombin and A23187 stimulate significant increases in cyclic GMP by 30 s; maximum increases were reached by 2 min. In monolayers exposed to thrombin, cyclic GMP levels slowly returned to baseline by 20 min. By contrast, cyclic GMP levels in monolayers exposed to A23187 remained half-maximally elevated for at least 40 min (Fig. 1 A) . In monolayers preincubated with 1 mM MIX (Fig. 1 B) , maximal increases in cyclic GMP were obtained by 10 min in response to thrombin or A23187.
After 10 min, thrombin-induced increases in cyclic GMP slowly declined; by 40 min, cyclic GMP levels approached baseline and were comparable with those observed after 5-min incubation. Findings similar to those seen with thrombin were obtained with bradykinin and histamine. In contrast to the effect ofphysiologic stimuli, cyclic GMP levels remained maximally elevated for as long as 40 min in the presence of both A23187 and MIX (Fig.  1 B) . This observation suggests that exposure of endothelial monolayers to A23 187 results in a sustained activation ofguanylate cyclase, whereas exposure to thrombin, bradykinin, and histamine results in a transient activation of this enzyme. The concentration-response relationships of the effect of A23187 on PGI2 biosynthesis and cyclic GMP accumulation are shown in Fig. 2 . During a 5-min incubation period, maximal increases in P12 production and cyclic GMP accumulation between 4 and 10 AM of A23187. Significant increases in cyclic GMP were observed with 0.04 ,M A23187, whereas 0.1 M A23187 was required to induce significant increases in PGI2 biosynthesis. Half-maximal increases in cyclic GMP and PGI2 production were obtained with 0.1 and 0.4 MM of A23187, respectively (Fig. 2 A) . In the presence of MIX, exposure of endothelial monolayers to A23187 produced much larger increases in cyclic GMP (Fig. 2 B) despite the inhibition of P12 biosynthesis observed with this agent (6, 8) . The dose-response relationships of the effect of A23187 on both cyclic GMP accumulation and P12 production parallel those observed in monolayers preincubated with buffer alone. Qualitatively, similar Concentration of A23187 (VjM) findings were obtained with thrombin, bradykinin, or histamine (data not shown).
To determine whether cyclic GMP mediates the induction or is involved in the regulation of PGI2 biosynthesis in the endothelium, the effects of several agents known to increase cyclic GMP accumulation in other cell types were tested. These included norepinephrine, acetylcholine, atriopeptin III, tert-butylhydroperoxide, and sodium nitroprusside. Although neither norepinephrine or acetylcholine, at concentrations ranging from 0.1 to 100 MM, had detectable effects on PGI2 biosynthesis or cyclic GMP accumulation, atriopeptin III, tert-butylhydroperoxide, and sodium nitroprusside stimulated significant increases in the intracellular concentration of cyclic GMP without an associated increase in PGI2 biosynthesis. The dose-response relationship of the effect of atriopeptin III on cyclic GMP accumulation in the absence and presence of MIX is shown in Fig.  3 . Even though the stimulatory effect ofatriopeptin III on cyclic GMP accumulation is comparable with that observed in response to thrombin, bradykinin, histamine, or A23187 (see Table I ), no increase in PGI2 production over basal levels was observed at any concentration of this peptide tested. Table IV shows that cyclic GMP levels were increased by about the same extent, either in the absence or presence of MIX, by tert-butylhydroperoxide, sodium nitroprusside, or A23 187. Like atriopeptin Ill, sodium nitroprusside had no effect on PGI2 biosynthesis; conversely, tert-butylhydroperoxide had a very small but statistically significant stimulatory effect. The data shown in Fig. 4 indicate that this effect of tert-butylhydroperoxide on PGI2 production is unrelated to its effect on cyclic GMP accumulation. First, significant increases in cyclic GMP were observed only in response to 40 or 100 MM tert-butylhydroperoxide, whereas PGI2 production increased progressively with up to 1,000 MM of this agent. Second, the concentration of tert-butylhydroperoxide that had the greatest effect on PGI2 production (i.e., 400 MM) had no detectable effect on cyclic GMP accumulation. These findings support the conclusion that an increase in the intracellular con- centration of cyclic GMP alone is insufficient to induce PG12 biosynthesis. It is also unlikely that cyclic GMP is directly involved in the regulation of PGI2 production, as preincubation of the endothelium with atriopeptin III, sodium nitroprusside, or tert-butylhydroperoxide had no effect on the subsequent with Hanks'-Hepes buffer followed by a 10-min incubation with the indicated addition. stimulation of PG12 biosynthesis by thrombin, A23 187, or arachidonic acid (data not shown).
Discussion
The results of the present study demonstrate that receptor-mediated stimuli ofPGI2 biosynthesis such as thrombin, bradykinin, and histamine, or the calcium ionophore A23187, stimulate cyclic GMP accumulation in primary monolayer cultures ofhuman umbilical vein endothelium. A similar correlation, specifically, between the stimulation ofphosphatidylinositol hydrolysis and cyclic GMP accumulation in response to activation ofmuscarinic-cholinergic, a-adrenergic, histamine Hi, bradykinin, angiotensin, and thrombin receptors, has previously been reported in a number of other cell types (for reviews see references 1-4, and reference 12). Although it has not yet been shown that phosphatidylinositol hydrolysis mediates the induction of P02 biosynthesis in endothelial cells, the observed increase in cyclic GMP provides indirect evidence suggesting that this pathway is likely to be involved.
Studies with the cyclic nucleotide phosphodiesterase inhibitor, MIX, show that increases in the intracellular concentration of cyclic GMP result from activation of guanylate cyclase and not from inhibition of cyclic GMP phosphodiesterase activity. At present, the mechanism by which physiologic stimuli mediate the activation of guanylate cyclase in intact cells is poorly understood. Although Ca2' is required for full expression of guanylate cyclase activity in cell-free systems (13), it is not known whether Ca2+ is the primary mediator of hormonal activation of guanylate cyclase in intact cells (14) . In some cell types, hormonally induced increases in cyclic GMP can be blocked by agents that interfere with the release or metabolism of unsaturated fatty acids (15, 16) . On the basis ofthese and other studies that show that unsaturated fatty acids and fatty acid peroxides can activate guanylate cyclase directly (17) , it has been concluded that these substances are the physiological activators of soluble guanylate cyclase in intact cells. However, evidence is given here that clearly shows that neither arachidonic acid nor its metabolites are involved in mediating the effects ofstimulatory agonists with respect to activation of guanylate cyclase. First, exposure of endothelial monolayers to arachidonic acid had no effect on cyclic GMP accumulation either in the absence or presence of MIX, despite marked production of PGI2. Second, inhibition ofcyclooxygenase activity with aspirin or ibuprofen had no effect on the stimulation of cyclic GMP accumulation observed in response to thrombin, bradykinin, histamine, or A23187. Third, inhibition of lipoxygenase and cyclooxygenase with ETYA had no effect on the stimulation of cyclic GMP accumulation by any of the agents tested. Fourth, inhibition of arachidonic acid release by quinacrine, presumably via inhibition ofphospholipase A2 activity, had no effect on increases in the intracellular concentration of cyclic GMP induced by any of the stimuli tested. These findings strongly support the view that activation ofguanylate cyclase is not mediated by arachidonic acid or by its metabolites, which include products of cyclooxygenase activity such as prostaglandin endoperoxides, PG12, and/or products of lipoxygenase activity such as 1 5-hydroxyeicosatetraenoic acid. The activation of guanylate cyclase must therefore be mediated by a factor generated by an initial step in the stimulusresponse coupling mechanism. Although it has not yet been established that extracellular signals stimulate Ca2" mobilization via phosphatidylinositol hydrolysis in endothelial cells, it is clear that Ca2' plays an important role in mediating the effects of these agents. It is therefore likely that Ca2+ is involved in the activation of guanylate cyclase in these cells. A central role for Ca2+ in the activation of guanylate cyclase is also suggested by the observation that the stimulatory effects of A23 187, and particularly of thrombin, on cyclic GMP accumulation are dependent on the presence of extracellular Ca2+. It is interesting to note that PG12 production in response to thrombin, but not A23187, was unaffected by the absence of extracellular Ca2+. This observation suggests that different pools ofCa2' are involved in mediating the effects of thrombin with respect to the biosynthesis of PG12 and cyclic GMP. The interaction of thrombin with its putative receptor may simultaneously trigger the activation oftwo parallel pathways, one leading to PG12 production and the other to cyclic GMP accumulation.
Examination of the time-courses and dose-response relationships of the effect of thrombin and A23187 suggests that a close, albeit undefined, relationship clearly exists between enhanced production of P0I2 and cyclic GMP accumulation. Significant increases in cyclic GMP were observed within 30 s of the addition of a stimulus to endothelial monolayers. Maximal increases in cyclic GMP, attained by 2 min, slowly returned to baseline by 20 min in the presence ofthrombin, histamine, and bradykinin, whereas they remained half-maximally elevated for at least 40 min in the presence ofA23 187. These findings suggest that guanylate cyclase is rapidly activated upon exposure of the endothelium to a stimulus, and that it remains in an activated state for a relatively long period of time. The induction of P0I2 biosynthesis also occurs very rapidly. Studies with the thrombin inhibitor DAPA (dansylarginine-N-(3-ethyl-1,5-pentanediyl)amide) (18) , indicate that exposure of the endothelium to active thrombin for as little as 6 s is sufficient to induce maximal release of PG12 (Brotherton, A. F. A., unpublished results). The concentration response relationships ofeach stimulus tested with respect to both PG12 production and cyclic GMP production were also found to be nearly identical, with the exception that a somewhat lower concentration of each agent stimulated a significant increase in cyclic GMP without effect on PG12 production.
Investigation of the effects of a number of agents known to increase cyclic GMP accumulation in other cell types provides evidence which suggests that an increase in the intracellular concentration ofcyclic GMP does not, by itself, mediate the induc-tion ofPGI2 biosynthesis in endothelial cells. Although significant increases in cyclic GMP were observed upon exposure of the endothelium to sodium nitroprusside or atriopeptin III, no increase in PGI2 production over baseline was observed. Since sodium nitroprusside and atriopeptin III have been shown to activate only the soluble (19) or particulate (20) forms of guanylate cyclase, respectively, it is reasonable to conclude that one or both of these agents increases cyclic GMP levels via the same mechanism as stimuli of PGI2 biosynthesis. Although tert-butylhydroperoxide had a small stimulatory effect on PGI2 production, it is unlikely that this effect is mediated by cyclic GMP, as higher concentrations ofthis agent stimulated larger increases in PGI2 without a concomitant effect on cyclic GMP accumulation. These findings argue against a primary role for cyclic GMP in mediating the induction ofPGI2 biosynthesis in response to extracellular stimuli.
Even though a wide variety of hormones, regulatory substances, experimental conditions, and drugs have been reported to increase the intracellular concentration of cyclic GMP in an equally wide variety of intact tissue and cell preparations, the precise physiological role of this cyclic nucleotide remains a mystery. By analogy with cyclic AMP, it has been assumed that cyclic GMP functions as an intracellular messenger for at least some of the extracellular signals that affect cyclic GMP levels. However, in sharp contrast to the well-characterized cyclic AMP system, there are only a few cell types in which unequivocal effects of cyclic GMP have been demonstrated. Most notably, there is convincing evidence that cyclic GMP mediates relaxation of both vascular and nonvascular smooth muscle (21, 22) , and that it plays a central role in the regulation of rod membrane voltage (23, 24) . It has been suggested by Walter (25) that difficulties encountered with establishing a clear-cut role for cyclic GMP may stem from a dogmatic adherence to the criteria developed by Sutherland et al. (26) for cyclic AMP. For example, the inability to correlate a hormone or drug-induced change in the cellular level of cyclic GMP with the physiological effect produced by these agents, or the inability to mimic the hormone or drug-induced physiological effect by extracellular application of cyclic GMP or cyclic GMP analogues, may in fact be attributable to the likelihood that the induction of the effect involves several second messengers. In such a case, Ca2' may function as the primary intracellular messenger, while cyclic GMP may have an important, albeit subtle, role in the short-or perhaps long-term modulation ofthe response. Experimentally, it would be difficult to mimic the action of cyclic GMP solely by manipulating the intracellular concentration of the cyclic nucleotide or by the addition of analogues if it acts to modulate the effects of the primary intracellular messenger. These experimental problems are further confounded by the limited understanding of the effector mechanisms of cyclic GMP in intact, physiologically responsive cells.
In light of the above considerations, full appreciation and interpretation of the results of the present study must await further investigation of the mechanism of action of cyclic GMP in these cells. Results ofpreliminary studies indicate that thrombin and A23 187 stimulate specific protein phosphorylation in intact primary human umbilical vein endothelium (27) ; studies are currently in progress to determine whether cyclic GMP mediates this response.
Although it is clear that cyclic GMP does not, by itself, mediate the induction of PGI2 biosynthesis in the endothelium, it may have an important role in modulating this response. For example, it is possible that cyclic GMP is involved in mediating the reuptake of Ca2" into intracellular stores. Alternatively, increases in the intracellular concentration of cyclic GMP that occur as a result of the induction of PGI2 biosynthesis by extracellular stimuli may, by some mechanism, trigger the synthesis of cyclooxygenase. This latter possibility is particularly intriguing as we have shown that this enzyme is rapidly deactivated as a result of PGI2 biosynthesis (28) .
At present, the only other well-described cell culture system available for investigation of physiological role of cyclic GMP is the murine neuroblastoma clone N 1 E-115. These cells were originally derived from a neuroblastoma and are reported to display many of the characteristic properties of normal differentiated neurons (29) . Although the stimulation of neurotransmitter receptors on these cells by muscarinic or histamine HI agonists, bradykinin, or thrombin, has been shown to cause rapid and transient increases in cyclic GMP that are dependent on the presence of extracellular Ca2` (29, 30) , the role of cyclic GMP in mediating or modulating the effects of these agents is not known. In sharp contrast to the findings of the present study, it has been suggested (30) that increases in cyclic GMP formation observed in response to stimulation of neurotransmitter receptors involves the release of arachidonic acid, and that an oxidative metabolite of this fatty acid stimulates soluble guanylate cyclase activity.
For many reasons, primary monolayer cultures of human umbilical vein endothelium provide an ideal model system for investigation of the role of cyclic GMP in signal transduction. Most importantly, these cells represent a homogeneous population of normal, untransformed human cells that are responsive to a wide variety of agents, exhibit numerous, well-described properties and physiologic responses, and are easy to grow. In addition, as the results of the present study show, the induction of PGI2 biosynthesis is closely associated with cyclic GMP accumulation; and, the activation of guanylate cyclase is mediated by a factor or factors generated by an initial step in the stimulusresponse coupling mechanism and not by oxidative metabolites of arachidonic acid. The marked and relatively prolonged activation of guanylate cyclase, which results in the maintenance of a significant, net increase in the intracellular concentration of cyclic GMP for several minutes, may ultimately provide insight as to the mechanism of action of cyclic GMP in these cells. Lastly, we have found (31) that early passage (1st through 3rd) of primary cultures of human umbilical vein endothelium results in a progressive, parallel loss of the capacity of these cells to produce PGI2 or to synthesize cyclic GMP in response to extracellular stimuli. As these passaged cells retain all other characteristic morphologic and physiologic properties of primary endothelial cultures (32) , it is clear that the co-availability of physiologically responsive (i.e., with respect to PGI2 and cyclic GMP biosynthesis) and progressively nonresponsive populations of the same cell type provides a unique opportunity to examine the factors involved in the expression of stimulus-response coupling mechanisms as well as the regulatory role of cyclic GMP.
